TrueWealth by TrueData – Live AI Summaries & Real-Time BSE/NSE Corporate Announcements
Copyright © TrueWealth 2025
Made with in INDIA
TrueData – Authorized Market Data Vendor for NSE, BSE, MCX (Official Logo)
Latest AnnouncementsToday 0
Upcoming Events
News Feed

  • No Data Found

P

Procter & Gamble Health Ltd

PGHL

pghealthindia.com NSE PGHL BSE500126 ISIN: INE199A01012
₹5766.6
0.11% (+6.10)
Website

pghealthindia.com

NSE
NSE

PGHL

BSE
BSE

500126

ISIN

INE199A01012

Announcement Post Market Close
Intimation :: AGM
Aug 12 2026, 04:53:19 PM

59Th Annual General Meeting Of The Company

The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.

Procter & Gamble Health Ltd
Since 1967

Procter & Gamble Health Ltd (PGHL) is a leading healthcare company in India, renowned for its focus on pharmaceutical and over-the-counter (OTC) healthcare products. As a subsidiary of Procter & Gamble (P&G), the company leverages global expertise to develop, manufacture, and distribute a variety of prescription medicines, nutritional supplements, and consumer health products. PGHL’s product suite encompasses therapeutic areas such as vitamins, minerals, anti-allergic, gastro-intestinal, and gynecological health.

Sector
Pharmaceuticals & Healthcare Sector
Recent Announcements (…Last 3 Days)
P
12 Aug 2026•16:53:19
Intimation::AGM
59Th Annual General Meeting Of The Company

The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.

P
12 Aug 2026•16:48:43
General::BRSR
Business Responsibility and Sustainability Reporting (BRSR)

The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.

P
12 Aug 2026•16:44:19
General::Reg 34(1) Annual Report
Reg. 34 (1) Annual Report.

Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.

P
12 Aug 2026•16:38:34
General::AGM
Notice Calling The 59Th Annual General Meeting Of The Company.

Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.

P
10 Aug 2026•18:53:04
Intimation::Record Date
Record Date For Purpose Of Dividend

Record Date for Purpose of Dividend

P
06 Aug 2026•14:05:49
General::Press/Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.

P
06 Aug 2026•14:03:53
Outcome::Financial Results
Unaudited Financial Results For The Quarter Ended June 30, 2026

Unaudited Financial Results for the Quarter ended June 30, 2026

P
06 Aug 2026•14:00:23
Outcome::Board Meeting Outcome
Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting.

truewealth
Request an update
Procter & Gamble Health Ltd
Pharmaceuticals & Healthcare SectorSince 1967
About

Procter & Gamble Health Ltd (PGHL) is a leading healthcare company in India, renowned for its focus on pharmaceutical and over-the-counter (OTC) healthcare products. As a subsidiary of Procter & Gamble (P&G), the company leverages global expertise to develop, manufacture, and distribute a variety of prescription medicines, nutritional supplements, and consumer health products. PGHL’s product suite encompasses therapeutic areas such as vitamins, minerals, anti-allergic, gastro-intestinal, and gynecological health.

With its head office in Mumbai, PGHL maintains a robust pan-India distribution network ensuring significant market reach. The company also operates a manufacturing facility in Goa and follows international quality standards in line with P&G’s global compliance and governance policies. Strategic collaborations and ongoing investments in research and development underpin the company’s strong presence in India’s healthcare landscape.

Business Model & Strategy

Procter & Gamble Health Ltd generates revenue primarily through the manufacture, marketing, and sale of branded prescription medicines and OTC healthcare products. Its portfolio caters to both acute and chronic lifestyle-related conditions, supported by healthcare professionals and an extensive distribution network involving wholesalers, pharmacies, and hospitals. PGHL's strategy emphasizes continuous product innovation, building doctor-patient awareness, and expanding access to healthcare.

Growth vectors include launching new molecule formulations, leveraging P&G’s global brands and R&D pipeline, and scaling its consumer health segment. The company also seeks additional revenue streams from export markets and institutional sales, while focusing on operational efficiency and regulatory compliance.

Management Overview
8 Members
Mr.Subramanian Madhavan
Non-Executive - Independent Director-Chairperson
Mr.Milind Thatte
Executive Director
Mr.Lokesh Chandak
Executive Director
Mr.Aalok Agrawal
Non-Executive - Non Independent Director
Ms.Seema Sambasivan
Non-Executive - Non Independent Director
Ms.Krishna Sarma
Non-Executive - Independent Director
Mr.Sharad Tyagi
Non-Executive - Independent Director
Ms.Zeal Shah
Company Secretary & Compliance Officer
Awards & Recognition
5 Awards
  • Asia's Most Trusted Companies Award (2024) by International Brand Consulting Corporation
  • Recognized in 'Top 50 Most Innovative Companies in Healthcare 2024' by Frost & Sullivan
  • Consistent A+ rating for Corporate Governance (2023–24) by BSE Limited
  • Great Place to Work® Certified Organization (2024–25) in India
  • Member of the United Nations Global Compact (Sustainability Commitment, 2024)
Market Information

This stock in not included in any Index

ISIN INE199A01012
Sector Pharmaceuticals & Healthcare
IndustryPharmaceuticals
Company Timeline

57+ Years of Excellence | 7 Major Milestones

1967

Company incorporated as Merck Limited in India.

1981

Listed on the Bombay Stock Exchange (BSE).

2000

Expanded into OTC and nutritional health product segments.

2018

Procter & Gamble acquires majority stake via global Merck Consumer Health business acquisition.

2019

Company renamed as Procter & Gamble Health Ltd.

2023

Receives approvals for new therapeutic product launches in women’s health and vitamin categories.

2024

Initiates digital transformation in sales and supply chain; scales exports to new international markets.

Coming Soon

The Next Evolution

Contact Information
Registered Office

P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E)

Tel: 022-68669000,

Fax: 022-25186828,

Email: investorgrievance.im@pg.com

Website: pghealthindia.com

Registrars

KFin Technologies Ltd

Tel: Toll Free No.: 1800-309-4001

Email: einward.ris@kfintech.com

Corporate Actions
22
PurposeEx DateRecord DateBC StartBC End
Final Dividend
₹45 per share
27 Aug 2026
Thursday
27 Aug 2026
Thursday
-
-
Special Dividend
₹50 per share
12 Feb 2026
Thursday
12 Feb 2026
Thursday
-
-
Interim Dividend
₹110 per share
12 Feb 2026
Thursday
12 Feb 2026
Thursday
-
-
Final Dividend
₹45 per share
22 Aug 2025
Friday
22 Aug 2025
Friday
-
-
Interim Dividend
₹80 per share
21 Feb 2025
Friday
21 Feb 2025
Friday
-
-
Final Dividend
₹60 per share
28 Nov 2024
Thursday
-
29 Nov 2024
Friday
05 Dec 2024
Thursday
Special Dividend
₹150 per share
14 Feb 2024
Wednesday
14 Feb 2024
Wednesday
-
-
Interim Dividend
₹50 per share
14 Feb 2024
Wednesday
14 Feb 2024
Wednesday
-
-
Final Dividend
₹50 per share
23 Nov 2023
Thursday
-
24 Nov 2023
Friday
30 Nov 2023
Thursday
Interim Dividend
₹45 per share
13 Feb 2023
Monday
13 Feb 2023
Monday
-
-
Final Dividend
₹11.50 per share
15 Nov 2022
Tuesday
-
17 Nov 2022
Thursday
23 Nov 2022
Wednesday
Interim Dividend
₹41 per share
12 May 2022
Thursday
13 May 2022
Friday
-
-
Special Dividend
₹90 per share
02 Nov 2021
Tuesday
-
05 Nov 2021
Friday
11 Nov 2021
Thursday
Final Dividend
₹40 per share
02 Nov 2021
Tuesday
-
05 Nov 2021
Friday
11 Nov 2021
Thursday
Final Dividend
₹42 per share
18 Nov 2020
Wednesday
-
20 Nov 2020
Friday
26 Nov 2020
Thursday
Special Dividend
₹188 per share
18 Nov 2020
Wednesday
-
20 Nov 2020
Friday
26 Nov 2020
Thursday
Special Dividend
₹416 per share
23 May 2019
Thursday
-
25 May 2019
Saturday
31 May 2019
Friday
Final Dividend
₹24 per share
23 May 2019
Thursday
-
25 May 2019
Saturday
31 May 2019
Friday
Dividend
₹15 per share
21 May 2018
Monday
-
23 May 2018
Wednesday
01 Jun 2018
Friday
Dividend
₹11 per share
25 May 2017
Thursday
-
29 May 2017
Monday
31 May 2017
Wednesday
Dividend
₹7.50 per share
22 Apr 2016
Friday
-
26 Apr 2016
Tuesday
28 Apr 2016
Thursday
Dividend
₹6 per share
30 Mar 2015
Monday
-
06 Apr 2015
Monday
08 Apr 2015
Wednesday
Interim Dividend
Final Dividend
Dividend
Bonus
Split
Rights Issue
Other
.dsf..
Market Cap
₹9,588 Cr.
Curr. Price
₹5,767
52W High/Low
₹6,975 / 4,707
P/E (TTM)
28.9
Book Value
₹447.37
Price To Book Ratio
12.91
ROE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
27.64 %
ROCE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
41.56 %
EPS (TTM)
blog-img
What is EPS & what is its significance?
₹199.89
Face Value
₹10.00
Dividend Yield
3.55 %
Manage Ratio
11 ratios selected

Date Basis

Time Range

EPS
truewealth
Request an update
FINANCIALS
Revenue
+3.8%
1,446.8 Cr
3Y +18%
5Y +43%
HIST AVG
Operating Income
+4.5%
436.0 Cr
3Y +35%
5Y +77%
HIST AVG
Net Income
+11.7%
334.0 Cr
3Y +46%
5Y +89%
HIST AVG
EPS
+11.7%
201.0
3Y +46%
5Y +89%
HIST AVG
Op. Cash Flow
-33.3%
337.0 Cr
3Y -9%
5Y -4%
HIST AVG
Note: Results are currently being updated and quality-checked. Some entries may be missing or incomplete—please check back soon for fully verified data.
PGHL - Quarterly Results

Standalone Figures in Rs. Crores

Quarterly Results+Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026TTM
Income + - - - - - - - - 226 232 212 249 251 232 - - - 271 246 222 288 276 283 270 299 301 315 326 307 311 315 255 286 317 314 314 343 - 378 374 3680
Expenses + - - - - - - - - 174 172 194 185 184 179 - - - 193 160 196 244 202 223 205 244 214 210 247 263 223 215 192 243 205 192 236 254 - 269 241 2700
Profit + - - - - - - - - 48 52 715 41 44 36 - - - 59 68 16 34 55 45 51 41 64 77 59 30 66 72 47 17 82 91 61 66 - 78 95 960
Tax +--------19194232317---181910101915141323281914222816629311723-3139330
EPS + - - - - - - - - 20 25 8 25 27 22 - - - 36 41 10 20 33 27 31 25 38 46 36 18 40 43 28 10 50 55 37 40 - 47 57 580
Ratios +-
Cash Flow

Standalone Figures in Rs. Crores

Quarterly Cash FlowJun 2016

Sep 2016

Dec 2016

Mar 2017

Jun 2017

Sep 2017

Dec 2017

Mar 2018

Jun 2018

Sep 2018

Dec 2018

Mar 2019

Jun 2019

Sep 2019

Dec 2019

Mar 2020

Jun 2020

Sep 2020

Dec 2020

Mar 2021

Jun 2021

Sep 2021

Dec 2021

Mar 2022

Jun 2022

Sep 2022

Dec 2022

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

-
Cash Flow Operating------------------103-247--29-170-137-236-75-228-119169---338--
Cash Flow Investing-------------------15--32--4--26--28--22--5--7-1010---1--
Cash Flow Financing-------------------384--387--218--289--22--98--85--418--101-235----344--
Cash Increase Decrease-------------------297--172--251--145-87-116--14--197-28-56----5--
Net Cash And Cash Equivalent------------------636-636-464-464-319-319-435-435-239239---182--
Balance Sheet

Standalone Figures in Rs. Crores

Annual Balance Sheet+Mar 2016Mar 2017Dec 2018Mar 2019Mar 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026-
Assets + - - 1,759 - - 986 894 1,101 794 794 841-
Equity And Liabilities + - - 1,759 - - 986 894 1,101 794 794 841-
Shareholding Pattern

Numbers in Percentages

Quarterly SHP

Announcement Date

Jun 2016

30 Jun '16

Sep 2016

30 Sep '16

Dec 2016

31 Dec '16

Mar 2017

31 Mar '17

Jun 2017

30 Jun '17

Sep 2017

30 Sep '17

Dec 2017

31 Dec '17

Mar 2018

31 Mar '18

Jun 2018

19 Jul '18

Sep 2018

19 Oct '18

Dec 2018

04 Sep '19

Mar 2019

04 Sep '19

Jun 2019

03 Sep '19

Sep 2019

22 Oct '19

Dec 2019

10 Jan '20

Mar 2020

21 Apr '20

Jun 2020

20 Jul '20

Sep 2020

06 Nov '20

Dec 2020

15 Jan '21

Mar 2021

20 Apr '21

Jun 2021

29 Jul '21

Sep 2021

19 Oct '21

Dec 2021

20 Jan '22

Mar 2022

21 Apr '22

Jun 2022

18 Jul '22

Sep 2022

02 Jan '23

Dec 2022

19 Jan '23

Mar 2023

20 Apr '23

Jun 2023

25 Jul '23

Sep 2023

26 Oct '23

Dec 2023

19 Jan '24

Mar 2024

12 Apr '24

Jun 2024

18 Jul '24

Sep 2024

07 Oct '24

Dec 2024

09 Jan '25

Mar 2025

21 Apr '25

Jun 2025

18 Jul '25

Sep 2025

20 Oct '25

Dec 2025

09 Jan '26

Mar 2026

20 Apr '26

Jun 2026

09 Jul '26

-
Goverments ------------------------------------------
Promoter And Promoter Group - - - - - - - - 51.80% 51.80% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82%-
Non Institutions --------35.40%36.24%37.22%36.53%35.26%34.13%33.91%33.17%32.53%30.96%30.31%30.00%29.93%33.94%33.69%33.71%33.64%29.51%29.42%29.15%28.74%28.49%27.92%28.21%27.23%26.74%26.46%27.11%27.03%27.04%27.37%28.31%29.42%-
FII - - - - - - - - - - - - - - - - - - - - - - - - - 6.05% 6.33% 6.72% 7.15% 7.38% 7.59% 6.24% 6.40% 6.61% 7.02% 6.87% 6.99% 7.24% 6.97% 6.20% 6.33%-
DII - - - - - - - - - - - - - - - - - - - - - - - - - 12.62% 12.43% 12.31% 12.30% 12.31% 12.67% 13.73% 14.55% 14.84% 14.71% 14.21% 14.16% 13.91% 13.84% 13.67% 12.44%-
Total --------100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-

Procter & Gamble Health Ltd

Pharmaceuticals
Last Updated: June 18, 2025

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd (PGHL) is a leading healthcare company in India, renowned for its focus on pharmaceutical and over-the-counter (OTC) healthcare products. As a subsidiary of Procter & Gamble (P&G), the company leverages global expertise to develop, manufacture, and distribute a variety of prescription medicines, nutritional supplements, and consumer health products. PGHL’s product suite encompasses therapeutic areas such as vitamins, minerals, anti-allergic, gastro-intestinal, and gynecological health.

With its head office in Mumbai, PGHL maintains a robust pan-India distribution network ensuring significant market reach. The company also operates a manufacturing facility in Goa and follows international quality standards in line with P&G’s global compliance and governance policies. Strategic collaborations and ongoing investments in research and development underpin the company’s strong presence in India’s healthcare landscape.

Pharmaceuticals & Healthcare SectorSince 1967
Business Model & Strategy

Procter & Gamble Health Ltd generates revenue primarily through the manufacture, marketing, and sale of branded prescription medicines and OTC healthcare products. Its portfolio caters to both acute and chronic lifestyle-related conditions, supported by healthcare professionals and an extensive distribution network involving wholesalers, pharmacies, and hospitals. PGHL's strategy emphasizes continuous product innovation, building doctor-patient awareness, and expanding access to healthcare.

Growth vectors include launching new molecule formulations, leveraging P&G’s global brands and R&D pipeline, and scaling its consumer health segment. The company also seeks additional revenue streams from export markets and institutional sales, while focusing on operational efficiency and regulatory compliance.

Management Overview 8 Total Members
logo
Mr.Subramanian Madhavan
Non-Executive - Independent Director-Chairperson
logo
Mr.Milind Thatte
Executive Director
logo
Mr.Lokesh Chandak
Executive Director
logo
Mr.Aalok Agrawal
Non-Executive - Non Independent Director
logo
Ms.Seema Sambasivan
Non-Executive - Non Independent Director
logo
Ms.Krishna Sarma
Non-Executive - Independent Director
logo
Mr.Sharad Tyagi
Non-Executive - Independent Director
logo
Ms.Zeal Shah
Company Secretary & Compliance Officer
Awards & Recognition 5 Awards
Asia's Most Trusted Companies Award (2024) by International Brand Consulting Corporation
Recognized in 'Top 50 Most Innovative Companies in Healthcare 2024' by Frost & Sullivan
Consistent A+ rating for Corporate Governance (2023–24) by BSE Limited
Great Place to Work® Certified Organization (2024–25) in India
Member of the United Nations Global Compact (Sustainability Commitment, 2024)
Market Information
Included In

This stock in not included in any Index

Details
ISIN: INE199A01012
Sector: Pharmaceuticals & Healthcare
Industry: Pharmaceuticals
Company Timeline
57+ Years of Excellence
7 Major Milestones
1967
Company incorporated as Merck Limited in India.
1981
Listed on the Bombay Stock Exchange (BSE).
2000
Expanded into OTC and nutritional health product segments.
2018
Procter & Gamble acquires majority stake via global Merck Consumer Health business acquisition.
2019
Company renamed as Procter & Gamble Health Ltd.
2023
Receives approvals for new therapeutic product launches in women’s health and vitamin categories.
2024
Initiates digital transformation in sales and supply chain; scales exports to new international markets.
Coming Soon: The Next Evolution
Contact Information
Registered Office
P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E)
Tel: 022-68669000,
Fax: 022-25186828,
Email: investorgrievance.im@pg.com
Website: pghealthindia.com
Registrars
KFin Technologies Ltd
Tel: Toll Free No.: 1800-309-4001
Email: einward.ris@kfintech.com

Peer Comparison

Part of This stock in not included in any Index
S.No.Company NameCMP (₹)Market Cap (₹ Cr)Div Yld (%)NP Qtr (₹ Cr)Qtr Profit Var (%)Sales Qtr (₹ Cr)Qtr Sales Var (%)ROCE (%)ROE (%)Book Value (₹)EPS TTM (₹)TTMPE Ratio (₹)
Not Found Data

Coming Soon

Heatmap View

Premium Feature
CompanyCMP (₹)MCap (₹ Cr)EPS TTM (₹)
Not Found Data

Financial Ratios

Premium Feature
Company NameP/E (TTM)EPS (₹)D/ENPMGPMROE (%)ROCE (%)P/B
Not Found Data

Coming Soon